baricitinib breez phase
studi atop dermat
primari endpoint met two atop dermat studi
along partner announc posit top-lin result
phase studi adult patient moder sever atop
dermat ad studi demonstr statist signific number patient
clear almost clear skin iga score greater equal
improv iga scale week efficaci data baricitinib
provid note dupix show placebo adjust improv iga
patient week approv entitl tier doubl digit
royalti rang world-wide baricitinib sale also
develop wholly-own topic ruxolitinib formul ad current
undergo phase studi reiter buy rate inci multipl shot goal
ad rais po higher probabl approv baricitinib
safeti baricitinib compar placebo common treatment-
emerg advers event common cold nasopharyng headach
contrast label olumi baricitinib moder sever rheumatoid arthriti
ra includ black box warn seriou infect malign thrombosi
lack venou thromboembol major advers cardiovascular event ad
studi therefor allevi safeti concern though note cardiovascular
risk ad level ra
competit heat jak ad
oral administr potenti price competit dupix give baricitinib
edg approv therapi ad view compet jak inhibitor pfe
abrocitinib abbv upadacitinib data expect respect
howev abbv decis seek fda approv dose dose
may indic potenti safeti concern given limit phase top-lin inform
provid await full data present upcom scientif confer
compar compet therapi top-lin result three phase studi
baricitinib ad also expect later year
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani focus drug
develop hematology/oncolog
inflamm multipl market product
includ inhibitor jakafi approv
myelofibrosi polycythemia vera olumi
baricitinib approv ra eu us
iclusig cml emerg rich clinic
rate share buy see signific
valu market product jakafi ruxolitinib
mf pv see signific potenti
compani robust pipelin olumi
approv eu us ruxolitinib gvhd ad
fgfr inhibitor liquid solid
po deriv probability-adjust npv analysi includ
jakafi call jakavi ex-u mf pv jakafi/itacitnib gvhd
baricitinib iclusig pemigatinib ruxolitinib
cream also includ approx net cash use wacc
downsid risk price object weaker-than-expect sale jakafi mf
pv unfavor efficaci and/or safeti data pipelin asset clinic trial
earlier-than-expect more-than-expect competit jakafi approv
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
